Psoriatic Arthritis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
PSORIATIC ARTHRITIS PIPELINE ANALYSIS
• Psoriatic arthritis (PsA) is an inflammatory condition that causes inflammation of joints. Psoriatic arthritis affects both the skin and the musculoskeletal system.
• Musculoskeletal symptoms are joint pain, tenderness, morning stiffness, swelling, reduction in joint movement; skin symptoms like separation on the nail bed, reddening and thickness of the skin; other symptoms include general fatigue, inflammation of the membrane lining the eyelid.
• Psoriatic arthritis mainly affects the people, who are affected with psoriasis, a skin disease. This is due to the degeneration of the cartilages present in the joints.
• Psoriasis is indicated by scaly red and white skin patches, which will affect any joint in the body such as scalp, elbows, knees, including the spine and others. People with psoriatic arthritis are more likely to be prone to high blood pressure, heart disease, high cholesterol, and diabetes.
• Change of lifestyle such as limiting alcohol intake, weight management, physical exercise, etc. may also help in the treatment process.
• Psoriatic patients are at higher risk of developing other clinical conditions including CVD and other non-communicable diseases.
• The psoriatic arthritis is categorized into asymmetric psoriatic arthritis, symmetric psoriatic arthritis, distal interphalangeal predominant (DIP) psoriatic arthritis, spondylitis, and arthritis mutilans.
• Treatment for psoriatic arthritis depends on its asperity. Various prescribed drugs over-the-counter (OTC) drugs are available for treatment. Prescribed drugs for psoriatic arthritis include immune-suppressing drugs, Non-steroidal drugs, and various biologics.
• Biologics majorly works by stopping the inflammatory condition. Tumor necrosis factor (TNF) and interleukin (IL) inhibitors are mostly used to treat psoriatic arthritis. The current research trend depicts that more emphasis is given on enzyme inhibitors, as TNF alpha is one of the enzymes showing promising results in arthritis. Biosimilar TNF alpha inhibitors present a more significant challenge to broader uptake of Cosentyx and Taltz. The companies are developing new biologics based on IL-17 inhibitors.
• The psoriatic arthritis community has welcomed the recent label update approval of Novartis’ IL-17 inhibitor, Cosentyx. Humira is the preferred biologic to treat psoriatic arthritis due to its efficacy in the skin and joint symptoms.
• The drug shows the highest clinical efficacy of any biologic approved. The psoriatic arthritis market is expected to have a range of therapeutic options over the forecast period, including Eli Lilly’s Taltz (ixekizumab), AstraZeneca’s Lumicef (brodalumab) and Celgene’s oral therapy Otezla (apremilast). Taltz and Lumicef are expected to emerge as the leading drugs in the psoriatic market.
• Several drugs are into clinical testing which depicts the possibility of discovering new molecules with maximum activity and minimum side effects.
• The rise in the incidence of psoriatic arthritis increased awareness of healthcare professional and new product launch is said to drive the global psoriatic arthritis (PsA) treatment market during the forecast period.
• Whereas inadequate access to health care, cost, and availability of essential medicines and the lack of standardized tools for diagnosis and treatment will hamper the growth of global psoriatic arthritis (PsA) treatment market.
• Psoriatic arthritis (PsA) is an inflammatory condition that causes inflammation of joints. Psoriatic arthritis affects both the skin and the musculoskeletal system.
• Musculoskeletal symptoms are joint pain, tenderness, morning stiffness, swelling, reduction in joint movement; skin symptoms like separation on the nail bed, reddening and thickness of the skin; other symptoms include general fatigue, inflammation of the membrane lining the eyelid.
• Psoriatic arthritis mainly affects the people, who are affected with psoriasis, a skin disease. This is due to the degeneration of the cartilages present in the joints.
• Psoriasis is indicated by scaly red and white skin patches, which will affect any joint in the body such as scalp, elbows, knees, including the spine and others. People with psoriatic arthritis are more likely to be prone to high blood pressure, heart disease, high cholesterol, and diabetes.
• Change of lifestyle such as limiting alcohol intake, weight management, physical exercise, etc. may also help in the treatment process.
• Psoriatic patients are at higher risk of developing other clinical conditions including CVD and other non-communicable diseases.
• The psoriatic arthritis is categorized into asymmetric psoriatic arthritis, symmetric psoriatic arthritis, distal interphalangeal predominant (DIP) psoriatic arthritis, spondylitis, and arthritis mutilans.
• Treatment for psoriatic arthritis depends on its asperity. Various prescribed drugs over-the-counter (OTC) drugs are available for treatment. Prescribed drugs for psoriatic arthritis include immune-suppressing drugs, Non-steroidal drugs, and various biologics.
• Biologics majorly works by stopping the inflammatory condition. Tumor necrosis factor (TNF) and interleukin (IL) inhibitors are mostly used to treat psoriatic arthritis. The current research trend depicts that more emphasis is given on enzyme inhibitors, as TNF alpha is one of the enzymes showing promising results in arthritis. Biosimilar TNF alpha inhibitors present a more significant challenge to broader uptake of Cosentyx and Taltz. The companies are developing new biologics based on IL-17 inhibitors.
• The psoriatic arthritis community has welcomed the recent label update approval of Novartis’ IL-17 inhibitor, Cosentyx. Humira is the preferred biologic to treat psoriatic arthritis due to its efficacy in the skin and joint symptoms.
• The drug shows the highest clinical efficacy of any biologic approved. The psoriatic arthritis market is expected to have a range of therapeutic options over the forecast period, including Eli Lilly’s Taltz (ixekizumab), AstraZeneca’s Lumicef (brodalumab) and Celgene’s oral therapy Otezla (apremilast). Taltz and Lumicef are expected to emerge as the leading drugs in the psoriatic market.
• Several drugs are into clinical testing which depicts the possibility of discovering new molecules with maximum activity and minimum side effects.
• The rise in the incidence of psoriatic arthritis increased awareness of healthcare professional and new product launch is said to drive the global psoriatic arthritis (PsA) treatment market during the forecast period.
• Whereas inadequate access to health care, cost, and availability of essential medicines and the lack of standardized tools for diagnosis and treatment will hamper the growth of global psoriatic arthritis (PsA) treatment market.
